We can't find the internet
Attempting to reconnect
Something went wrong!
Hang in there while we get back on track
Micro-plastics as a source of contaminaion in pharmaceuticals
AI summary Read the abstract
This review examined how microplastics contaminate pharmaceutical manufacturing environments and products, discussing the potential health risks of plastic particle exposure through medicines and the pathways by which microplastics enter pharmaceutical supply chains.
Microplastics is becoming more widely acknowledged that —small plastic particles smaller than five millimeters—pose serious risks to human health and the environment. Both marine and terrestrial ecosystems have been impacted by these contaminants, which are either produced for use in goods like detergents and cosmetics or are derived from the breakdown of bigger plastic objects. Common varieties with distinct physical and chemical characteristics are polyethylene (PE), polypropylene (PP), polyvinyl chloride (PVC), and polystyrene (PS). Microplastics can travel thousands of kilometers from their source due to their endurance in the environment, which can have detrimental effects, especially on aquatic ecosystems. These particles are frequently mistaken for food by marine species, which can lead to physical harm, malnutrition, and the bioaccumulation of harmful compounds that might endanger human health by entering the food chain. Microplastics have been found in human biological samples, such as blood, lungs, and placental tissues, according to research. This raises concerns about long-term health impacts such inflammation, endocrine disruption, and possible carcinogenic dangers. Furthermore, microplastics have the potential to spread genes that cause antibiotic resistance, which makes public health issues more complex. Current efforts to evaluate pollution on a worldwide basis are hampered by difficulties in identifying and measuring microplastics, particularly smaller nanoplastics. This problem is made worse by the absence of defined procedures for reporting and sampling. Quick research, the development of efficient detection procedures, and strategies for mitigation are necessary to combat the escalating threat posed by microplastics. To preserve ecosystems and public health, cooperation between scientific groups and regulatory agencies is essential.
More Papers Like This
Impact of Microplastic Contaminants on Drug Stability and Safety
AI summary Read the abstract
Researchers reviewed how microplastic contaminants may alter the stability, bioavailability, and safety of pharmaceutical products by adsorbing drug compounds and releasing them unpredictably. Survey data from pharmaceutical quality assurance professionals and literature synthesis identified specific mechanisms by which MPs could degrade drug formulations, flagging an underexplored drug safety concern.
Detection and Analysis of Microplastics in Pharmaceutical Products
AI summary Read the abstract
This review paper summarizes existing research on how tiny plastic particles called microplastics might get into medicines, from packaging, tubing, and manufacturing equipment. It describes laboratory methods used to detect these particles and notes that whether they enter the human body through medicines or medical procedures, and what that might mean for health, is not yet well understood.
Considerations for the Pharmaceutical Industry Regarding Environmental and Human Health Impacts of Microplastics
AI summary Read the abstract
This review examines the responsibilities of the pharmaceutical industry in addressing microplastic pollution, discussing sources, environmental fate, and human health impacts of microplastics with attention to how the pharmaceutical sector both contributes to and can mitigate MP contamination. The authors outline mitigation and adaptation actions available to the industry as part of the broader societal response to plastic pollution.
Plastic particles in medicine: A systematic review of exposure and effects to human health
AI summary Read the abstract
Medical plastics including bags, containers, and administration sets release micro- and nanoplastics along with chemical additives that can interact with pharmaceutical constituents, creating an understudied route of direct human exposure. Both primary exposure (during medical treatment) and secondary environmental exposure (from hospital plastic waste disposal) represent potential health hazards.
Microplastic contamination in oral pharmaceuticals for pregnant women and children: A neglected direct exposure pathway
AI summary Read the abstract
Researchers found tiny plastic particles (microplastics) in common oral medicines and vitamins made for pregnant women and children, including capsules and pediatric vitamin drops. Some products, especially children's soft vitamin capsules, contained a wide mix of plastic types and dozens of particles per dose, while plain starch-based capsules had none detected. Since these medications are meant for the most vulnerable groups, this suggests drug manufacturing could be an overlooked source of microplastic exposure — and the study's authors argue drug makers should start testing for and limiting plastic contamination during production.
Research digests by email
When a large batch of papers lands in the Atlas, we read through it and send a short write-up of what stood out.